Damon Broyles Joins Cardio Diagnostics Holdings as Strategic Advisor

Cardio Diagnostics Holdings Inc. has recruited Damon Broyles, M.D., as a strategic advisor. Broyles will leverage his healthcare industry knowledge and experience to navigate complex challenges and capitalize on emerging opportunities in the cardiovascular disease, precision medicine, and innovation landscapes.

“Dr. Broyles is a highly respected clinical and thought leader in the healthcare industry, and we are thrilled to have him join Cardio Diagnostics as a strategic advisor,” Cardio Diagnostics Holdings CEO Meesha Dogan, Ph.D., said. “His extensive expertise and operational proficiency at the intersection of innovation, precision medicine, and emerging technologies make him the perfect addition to our team. We are confident that his insights and guidance will help us identify new growth opportunities, mitigate risks, and create long-term value for our company, customers, and stakeholders. With Dr. Broyles on board, we are excited to advance our mission of bringing artificial intelligence-powered precision cardiovascular medicine to patients worldwide.”

Broyles is currently vice president of Clinical Innovation at Mercy Technology Services (MTS), the technical support arm of Mercy Healthcare, where he leads the charge on clinical innovation initiatives. He also serves as medical director for the Multi-Cancer Early Detection program, emphasizing his dedication to cutting-edge solutions in healthcare. Broyles is a key figure in the development of Mercy’s Department of Precision Medicine. He serves as an informatics facilitator and innovator for both MTS and Mercy, where he is responsible for driving value-based population health initiatives, including one of the nation’s largest Accountable Care Organizations (ACOs). His leadership and strategic vision have played an integral role in the growth and success of the organization.

Broyles has developed a broad and expansive lens of the healthcare industry through a wide array of board appointments and advisory services for large technology firms, dynamic startups, and venture capital and institutional research teams. His experience and knowledge have helped cultivate innovation initiatives and development throughout the Midwest region in the areas of healthcare technology, clinical informatics, biotechnology, and entrepreneurship in medicine. He utilizes this unique expertise to enhance and optimize enterprise clinical systems for the 4,200 integrated providers, 44 hospitals, and 925 outpatient and clinic facilities encompassing the Mercy health system.
 
“I am thrilled to join Cardio Diagnostics and contribute my expertise in healthcare innovation and precision medicine,” Broyles stated. “As a strategic advisor, I am eager to collaborate with the team to drive innovation in the cardiovascular disease landscape. With the power of artificial intelligence and precision medicine, I believe that Cardio Diagnostics is poised to transform the field of cardiovascular medicine and improve patient outcomes on a global scale. I look forward to playing a role in advancing this mission and making a meaningful impact in the lives of patients and clinicians.”
 
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease to enable improved prevention, early detection, and assistance in treating cardiovascular disease.